Overview

Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease

Status:
COMPLETED
Trial end date:
2024-05-30
Target enrollment:
Participant gender:
Summary
This study will assess the effect of severe kidney impairment on the pharmacokinetics (PK), safety and tolerability of ZSP1273.
Phase:
PHASE1
Details
Lead Sponsor:
Guangdong Raynovent Biotech Co., Ltd
Treatments:
ZSP1273